Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX
Holding PTIX?
Track your performance easily
PTIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $1.87
Previous Close$0.5
Volume69.45K
Average Volume (3M)175.54K
Market Cap
$3.36M
Enterprise Value$2.31M
Total Cash (Recent Filing)$1.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Apr 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding6,794,821
10 Day Avg. Volume168,364
30 Day Avg. Volume175,545
Standard Deviation0.44
R-Squared0.00371
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Protagenic Therapeutics News
PremiumCompany Announcements
Protagenic Therapeutics Raises $1.275M for Growth Initiatives
PremiumCompany Announcements
Protagenic Therapeutics Secures $1.275M in Private Placement
Ownership Overview
6.71%
Insiders
0.89% Mutual Funds
0.19% Other Institutional Investors
91.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PTIX FAQ
What was Protagenic Therapeutics’s price range in the past 12 months?
Protagenic Therapeutics lowest stock price was $0.45 and its highest was $1.87 in the past 12 months.
What is Protagenic Therapeutics’s market cap?
Currently, no data Available
When is Protagenic Therapeutics’s upcoming earnings report date?
Protagenic Therapeutics’s upcoming earnings report date is Apr 01, 2024 which is 264 days ago.
How were Protagenic Therapeutics’s earnings last quarter?
Protagenic Therapeutics released its earnings results on Nov 16, 2021. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.12.
Is Protagenic Therapeutics overvalued?
According to Wall Street analysts Protagenic Therapeutics’s price is currently Overvalued.
Does Protagenic Therapeutics pay dividends?
Protagenic Therapeutics does not currently pay dividends.
What is Protagenic Therapeutics’s EPS estimate?
Protagenic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagenic Therapeutics have?
Protagenic Therapeutics has 6,794,821 shares outstanding.
What happened to Protagenic Therapeutics’s price movement after its last earnings report?
Protagenic Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -2.874%.
Which hedge fund is a major shareholder of Protagenic Therapeutics?
Among the largest hedge funds holding Protagenic Therapeutics’s share is Oracle Investment Management Inc. It holds Protagenic Therapeutics’s shares valued at N/A.
---
Protagenic Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.07%
12-Months-Change
Fundamentals
Return on Equity
-231.87%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
Protagenic Therapeutics
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
---
Technical Analysis
---